14th Asia-Pacific Breast Cancer Summit 2026 shared a post on LinkedIn:
“Endocrine resistance remains a defining challenge in the long-term management of HR-positive metastatic breast cancer (MBC). As treatment options expand, selecting the right sequential therapy at the right time is critical to sustaining disease control and preserving quality of life.
This focused session at APBCS 2026 will address practical approaches to tailoring treatment sequences, guided by evolving evidence, resistance patterns, and real-world clinical considerations.
Talk: Navigating Endocrine Resistance: Tailoring Sequential Treatments in HR+ MBC
Date: Saturday, 7 February 2026
Time: 16:15 – 16:45 (Malaysia Time)
Venue: St Giles Wembley Penang, Malaysia
Designed for medical oncologists and breast cancer specialists, this session offers actionable insights to support informed, patient-centric decision-making in advanced disease settings.
More posts about APBCS 2026.